TURKU - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, will today host a virtual R&D Day via webcast to present its R&D strategy and provide insight into Faron's two clinical stage programmes, Clevegen and Traumakine.

The event will take place today at 3.00 p.m. EEST, 1.00 p.m. BST, 8.00 a.m. EDT. Further to the announcement earlier today, no new price sensitive information will be disclosed.

Clevegen

Clevegen is Faron's wholly-owned novel precision cancer immunotherapy, targeting Clever-1 positive tumour associated macrophages (TAMs) in selected metastatic or inoperable solid tumours, currently under development in the ongoing phase I/II MATINS clinical trial. As announced this morning, the World Health Organization (WHO) has now accepted the proposed INN name of bexmarilimab for Clevegen.

About HIBISCUS

Human Interferon Beta In Severe CoronavirUS (HIBISCUS) study is a phase II/III pivotal, randomized, placebo controlled Traumakine study in severely ill COVID-19 patients. The study aims to recruit 350 patients with 1:1 randomization and patients will be followed for ventilation free days (VFD) and mortality over the 28 day period post first dosing. No corticosteroid use will be accepted in this study which is expected to enroll patients over 6-8 months throughout the US with many significant hospitals participating. The study's principal investigator will be Prof. Daniel Talmor from Harvard University's Beth Israel Deaconess Medical Center (BIDMC).

Contact:

James Stearns

Tel: +44 207 886 2500

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen, its precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures, has completed a phase III clinical trial in Acute Respiratory Distress Syndrome (ARDS). Plans for its future development are being finalised to avoid interfering steroid use together with Traumakine. Faron is based in Turku, Finland.

(C) 2020 Electronic News Publishing, source ENP Newswire